RIPK2 Inhibitor Scaffolds for Variable Inflammatory Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies for inflammatory and other diseases targeting pro-inflammatory signaling pathways are ineffective for a significant fraction of patients, necessitating the development of novel therapeutic molecules that modulate or inhibit these pathways.
Innovation Solution
Development of imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, or their pharmaceutically acceptable salts, which act as RIPK2 inhibitors to modulate the RIPK2-NOD signaling pathways, thereby treating associated diseases and disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies targeting pro-inflammatory signaling pathways are used, then some patients experience therapeutic benefits, but a significant fraction of patients show no response
Solution Approach 1:
The patent employs structure-activity relationship (SAR) analysis to systematically modify chemical parameters of the imidazo[1,2-a]pyridine core structure, including substituent variations at different positions (R1-R6 groups), to optimize RIPK2 inhibition potency and selectivity, thereby improving therapeutic effectiveness while reducing off-target effects
Solution Approach 2:
The patent divides the therapeutic approach into multiple compound series with distinct structural features (e.g., compounds of Formula I, II, III with different ring systems and substituent patterns), allowing selection of the most appropriate agent for different patient subsets based on disease characteristics and response profiles
2Reliability
If novel RIPK2 inhibitor compounds are developed, then therapeutic effectiveness is improved, but compound complexity increases
Solution Approach 1:
The patent introduces specific functional groups and substituents at particular positions on the imidazo[1,2-a]pyridine core (e.g., electron-withdrawing groups at C2, specific heteroatom placements) to achieve localized electronic and steric effects that enhance RIPK2 binding affinity and selectivity without requiring complex overall molecular architecture
Solution Approach 2:
The patent uses the imidazo[1,2-a]pyridine ring system as a structural intermediary that facilitates specific interactions with RIPK2 kinase domain residues, mediating the inhibition effect through key pharmacophoric features while maintaining a relatively simple and synthesizable core structure
Data Source
AI summary
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed herein, with the compounds of Formula (I), and pharmaceutically acceptable salts thereof, and the compositions comprising same.